Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton, R J; Figg, W D; Venzon, D J; Dalakas, M C; Bowden, C; Headlee, D; Reed, E; Myers, C E; Cooper, M R

Bitton, R J; Figg, W D; Venzon, D J; Dalakas, M C; Bowden, C; Headlee, D; Reed, E; Myers, C E; Cooper, M R.

Affiliation

Bitton RJ; Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

J Clin Oncol ; 13(9): 2223-9, 1995 Sep.

Article in En | MEDLINE | ID: mdl-7666080

Subject(s)

Nervous System Diseases/chemically induced; Suramin/adverse effects; Adult; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Melanoma/blood; Melanoma/drug therapy; Middle Aged; Motor Neuron Disease/chemically induced; Multivariate Analysis; Prostatic Neoplasms/blood; Prostatic Neoplasms/drug therapy; Sarcoma/blood; Sarcoma/drug therapy; Suramin/administration & dosage; Suramin/pharmacokinetics

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Suramin / Nervous System Diseases Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1995 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links